The impact of COVID-19 on ALL patients in Spain

How should we manage patients with acute lymphoblastic leukaemia during COVID-19?

Why the ADAURA study is a big step forward for NSCLC

KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma

Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab

Renal cell cancer: Highlights from ASCO 2020

FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advanced renal cell carcinoma

CAPIRI versus irinotecan for the treatment of advanced gall bladder cancer patients progressing on first-line chemotherapy

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Treating acute lymphoblastic leukaemia in the era of COVID-19